Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AML.-论文-万方医学网

作者： Jorge E,Cortes ^[1] ; Martin S,Tallman ^[2] ; Gary J,Schiller ^[3] ; Denise,Trone ^[4] ; Guy,Gammon ^[4] ; Stuart L,Goldberg ^[5] ; Alexander E,Perl ^[6] ; Jean-Pierre,Marie ^[7] ; Giovanni,Martinelli ^[8] ; Hagop M,Kantarjian ^[1] ; Mark J,Levis ^[9]

作者单位： Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[1] Memorial Sloan Kettering Cancer Center, New York, NY. ^[2] David Geffen School of Medicine at UCLA, Los Angeles, CA. ^[3] Daiichi Sankyo Pharma Development, San Diego, CA. ^[4] Hackensack University Medical Center, Hackensack, NJ. ^[5] Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. ^[6] Saint-Antoine Hospital, AH-HP-University Paris 6, Paris, France. ^[7] University of Bologna, Bologna, Italy; and. ^[8] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD. ^[9]

主题词成年人(Adult);老年人(Aged);抗肿瘤药(Antineoplastic Agents);苯并噻唑类(Benzothiazoles);剂量效应关系, 药物(Dose-Response Relationship, Drug);女(雌)性(Female);胃肠疾病(Gastrointestinal Diseases);基因复制(Gene Duplication);心脏病(Heart Diseases);血液病(Hematologic Diseases);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);男(雄)性(Male);中年人(Middle Aged);癌基因蛋白质类, 融合(Oncogene Proteins, Fusion);苯脲化合物(Phenylurea Compounds);蛋白激酶抑制剂(Protein Kinase Inhibitors);挽救疗法(Salvage Therapy);串联重复序列(Tandem Repeat Sequences);青年人(Young Adult);fms样酪氨酸激酶3(fms-Like Tyrosine Kinase 3)

DOI 10.1182/blood-2018-01-821629

PMID 29875101

发布时间 2021-02-02

检索历史清除

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AML.

Blood

相似文献

Blood

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in <i>FLT3</i>-ITD-mutated, relapsed or refractory AML.

Blood

相似文献

Blood

相关期刊

检索历史清除